Patient
P2B-009
completed Phase IIA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · CTRC Institute for Drug Development, University of Texas (San Antonio, TX) (Dr. Muller)
consented 2012-06-09
Adverse events
2
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 2
Grade 1 weight decreased with onset in cycle 4 (2012-08-30); assessed as not related to study drug (not related); resolved 2012-10-29.
Grade 1 vomiting with onset in cycle 1 (2012-06-29); assessed as related to study drug (possible); resolved 2012-06-30.
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.